TYRA

20.1201.98%
AF

Alan Fuhrman

Chief Financial Officer

Mr. Alan Fuhrman, CPA has been the Chief Financial Officer of Tyra Biosciences, Inc. since January 1, 2023. He had been Independent Non-Employee Director at Esperion Therapeutics, Inc. since March 16, 2020 until May 30, 2025, a biotechnology company focused on developing novel products for life-threatening infections from December 2017 to June 2020. Mr. Fuhrman had been a Director of Checkmate Pharmaceuticals, Inc. from June 2019 to May 31, 2022 and served as its Interim Chief Executive Officer & President from October 2021 to March 01, 2022. Mr. Fuhrman had been an Independent Director at SpringWorks Therapeutics, Inc. since August 2019 until July 01, 2025. He served as the Chief Financial Officer at Mirna Therapeutics, Inc. since September 16, 2015 to August 2017 and as its Principal Accounting Officer since December 2, 2016. Mr. Fuhrman was Chief Financial Officer of Amplyx Pharmaceuticals since January 8, 2018 until his retirement in June 2020. He has executive management experience with public and private companies in the life sciences and high technology industries. Mr. Fuhrman served as the Chief Financial Officer of Ambit Biosciences Corporation since October 2010 to November 2014 and served as its Principal Accounting Officer. He led Ambit through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. He served as the Chief Financial Officer of Naviscan, Inc. from November 2008 to September 2010. He served as Chief Financial Officer of Suneva Medical, Inc. He served as the Chief Financial Officer and Senior Vice President of OncoGenex Pharmaceuticals, Inc. from September 2004 to August 21, 2008. He served as a Senior Vice President and Chief Financial Officer of Sonus Pharmaceuticals Inc. since September 15, 2004 to August 2008 and also served as its Principal Accounting Officer. He served as the Chief Financial Officer and Senior Vice President of Capitalstream, Inc. He served as the President and Chief Operating Officer of Integrex, Inc., from 2002 until its acquisition by a public competitor in 2015. Mr. Fuhrman served as a Senior Vice President and Chief Financial Officer of Capital Stream, Inc. He served as the Chief Financial Officer of Medisystems Corporation and NeoPath, Inc. He practiced as a Certified Public Accountant with Coopers & Lybrand. He was a Director at Loxo Oncology, Inc. from January 12, 2015 to February 15, 2019. He served as Director of Healionics Corporation. Mr. Fuhrman holds a B.S. degree in Business Administration and Agricultural Economics from Montana State University-Bozeman. Mr. Fuhrman received his Certified Public Accountant Certification from the State of Oregon.

Positions